CELLECT BIOTECH/S (NASDAQ:APOP)’s share price was down 3.8% during trading on Wednesday . The company traded as low as $1.05 and last traded at $1.02. Approximately 4,276 shares traded hands during trading, a decline of 99% from the average daily volume of 369,235 shares. The stock had previously closed at $1.06.

A number of equities analysts recently commented on APOP shares. HC Wainwright set a $12.00 price target on shares of CELLECT BIOTECH/S and gave the stock a “buy” rating in a research note on Wednesday, December 12th. Zacks Investment Research raised shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Thursday, January 3rd.

The stock has a market cap of $5.60 million, a PE ratio of -0.70 and a beta of 2.43.

An institutional investor recently bought a new position in CELLECT BIOTECH/S stock. Susquehanna International Group Ltd. acquired a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,964 shares of the company’s stock, valued at approximately $25,000. CELLECT BIOTECH/S accounts for approximately 0.0% of Susquehanna International Group Ltd.’s holdings, making the stock its 28th largest position. Susquehanna International Group Ltd. owned about 0.22% of CELLECT BIOTECH/S as of its most recent filing with the Securities and Exchange Commission. 2.57% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/cellect-biotech-s-apop-shares-down-3-8/2891736.html.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Read More: How to invest in a bear market

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.